Breaking News

Antiverse Raises $9.3M, Enters Research Pact with Cystic Fibrosis Foundation

Funding to accelerate internal pipeline and advance lead antibody programs toward in vivo efficacy studies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Antiverse

Pictured: Murat Tunaboylu, Co-Founder and CEO, Antiverse, and Ben Holland, Co-Founder and CTO, Antiverse.

Antiverse, an AI-driven techbio company developing therapeutic antibodies for historically undruggable targets, has raised a $9.3 million Series A and announced a research agreement with the Cystic Fibrosis Foundation. The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures, and existing investors, bringing total funding to over $20 million. Proceeds will advance Antiverse’s internal pipeline toward in vivo efficacy studies and further sc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters